Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

被引：2

作者：

Brieva, Luis ^{[1
]}

Estruch, Bonaventura Casanova ^{[2
]}

Merino, Juan Antonio Garcia ^{[3
]}

Meca-Lallana, Virginia ^{[4
,5
]}

Rio, Jordi

Rodriguez-Antigueedad, Alfredo ^{[6
]}

Aguera, Eduardo ^{[7
]}

Ara, Jose Ramon ^{[8
]}

Luque, Adrian Ares ^{[9
]}

Garcia, Carmen Arnal ^{[10
]}

Blanco, Yolanda ^{[11
]}

Castillo-Trivino, Tamara ^{[12
]}

Costa-Frossard, Lucienne ^{[13
]}

Platas, Montserrat Gonzalez ^{[14
]}

Pascual, Lamberto Landete ^{[15
]}

Llaneza-Gonzalez, Miguel ^{[16
]}

Gines, Maria Luisa Martinez ^{[17
]}

Matias-Guiu, Jorge ^{[18
]}

Meca-Lallana, Jose E. ^{[19
]}

Bilbao, Mar Mendibe ^{[6
]}

Sempere, Angel Perez ^{[20
]}

Romero-Pinel, Lucia ^{[21
]}

Saiz, Albert ^{[22
]}

Moral, Ester ^{[23
,24
]}

机构：

[1] IRBLLEIDA, Hosp Arnau Vilanova, Lleida, Spain

[2] Hosp Universitari i Politecn Fe, Dept Neurol, Unit Neuroimmunol, Valencia, Spain

[3] Univ Autonoma Madrid, Fdn Invest Puerta Hierro, Madrid, Spain

[4] Hosp Univ Princesa, Dept Neurol, Multiple Sclerosis Unit, Madrid, Spain

[5] Hosp Univ Vall dHebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya, Serv Neurol Neuroimmunol, Barcelona, Spain

[6] Hosp Univ Cruces, Neuroimmunol & Multiple Sclerosis Unit, Baracaldo, Spain

[7] IMIBIC, Hosp Univ Reina Sofia, Neurol, Cordoba, Spain

[8] IIS Aragon, Hosp Univ Miguel Servet, Zaragoza, Spain

[9] Complejo Asistencial Univ Leon, Neurol, Leon, Spain

[10] Hosp Virgen Nieves, Granada, Spain

[11] Hosp Clin Barcelona, Un Neuroimmunol & Esclerosis multiple, Barcelona, Spain

[12] Biodonostia Hlth Res Inst, Neurol Dept, Basque Hlth Serv, Neurosci Area,Multiple Sclerosis Grp, San Sebastian, Spain

[13] Hosp Univ Ramon & Cajal, Fdn Invest Biomed IRyCIS, Serv Neurol, CSUR Esclerosis Multiple, Madrid, Spain

[14] Hosp Univ Canarias, Serv Neurol, Tenerife, Spain

[15] Hosp Univ Dr Peset, Serv Neurol, Valencia, Spain

[16] Complejo Hospitalario Univ Ferrol, Serv Neurol, La Coruna, Spain

[17] Hosp Gen Univ Gregorio Maranon, Serv Neurol, Madrid, Spain

[18] Univ Complutense Madrid, Hosp Clin San Carlos, Hlth Res Inst San Carlos IdISCC, Dept Neurol, Madrid, Spain

[19] IMIB Arrixaca, Hosp Clin Univ Virgen Arrixaca, Neurol Dept, CSUR Multiple Sclerosis & Clin Neuroimmunol Unit, Murcia, Spain

[20] Hosp Gen Univ Alicante, Neurol Serv, Alicante 03010, Spain

[21] Hosp Universitari Bellvitge IDIBELL, Dept Neurol, Multiple Sclerosis Unit, Lhospitalet De LLobregat, Barcelona, Spain

[22] Univ Barcelona, Hosp Clin, Inst Invest Biome August Pi Sunyer IDIBAPS d, Ctr Neuroimmunol, Barcelona, Spain

[23] Hosp Moises Broggi, Serv Neurol, Sant Joan Despi, Barcelona, Spain

[24] Hosp Gen Hospitalet, Serv Neurol, Lhospitalet De Llobregat, Barcelona, Spain

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2022年 / 63卷

关键词：

Relapsing multiple sclerosis; Disease modifying therapy; Benefit-risk; Therapy switching; Relapse; Washout period; INTERFERON-BETA; NATALIZUMAB; FINGOLIMOD; GUIDELINES; PREGNANCY; OUTCOMES; IMPACT; MRI;

D O I：

10.1016/j.msard.2022.103805

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: The increase in available disease modifying therapies (DMTs) for multiple sclerosis has led to greater emphasis on improving treatment sequencing paradigms. This article summarises the opinions from a panel of 25 experts on treatment switching approaches in relapsing multiple sclerosis (RMS).Methods: A modified Delphi consensus process was carried out to develop clinically relevant statements for aiding treatment decisions in patients with RMS between the 16th January and the 9th October 2019. A sub-group of two experts (core group) carried out an extensive review of the literature and formulated 106 statements for the expert panel to evaluate.Results: From a total number of 106 statements that were submitted to the expert panel for critical evaluation, consensus (at least 80% of the panelists agreed) was reached on 99 of them. These statements cover treatment objectives, reasons for DMT switching, suboptimal response criteria, strategies for treatment change and washout periods.Conclusion: The agreed statements provide up-to-date guidance on DMT sequencing for optimal patient management.

引用

页数：8

共 50 条

[41] Disease-modifying effect of circuit class therapy in patients with relapsing-remitting multiple sclerosis
Kolcava, J.
Vlckova, E.
Kocica, J.
Sladeckova, M.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 395 - 396
[42] Relapsing-remitting multiple sclerosis and oligoclonal band pattern during disease modifying drug therapy
Mares, J.
Herzig, R.
Urbanek, K.
Podivinsky, J.
Bekarek, V.
Sklenarova, J.
Zapletalova, J.
Hlustik, P.
Sladkova, V.
Dolezil, D.
Kanovsky, P.
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2007, 70 (06) : 674 - 677
[43] Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis
Macias-Islas, Miguel A.
Soria-Cedillo, Isaac F.
Velazquez-Quintana, Merced
Rivera, Victor M.
Baca-Muro, Veronica I.
Lemus-Carmona, Edith A.
Chiquete, Erwin
ACTA NEUROLOGICA BELGICA, 2013, 113 (04) : 415 - 420
[44] Myelopathic relapses predict treatment failure with disease modifying therapy in relapsing-remitting Multiple sclerosis
Chaudhuri, A.
Fuller, S.
Rabvukwa, P.
Mattoscio, M.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 482 - 482
[45] Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: No
Zajicek, John
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (09) : 1165 - 1166
[46] Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis
Miguel A. Macías-Islas
Isaac F. Soria-Cedillo
Merced Velazquez-Quintana
Victor M. Rivera
Verónica I. Baca-Muro
Edith A. Lemus-Carmona
Erwin Chiquete
Acta Neurologica Belgica, 2013, 113 : 415 - 420
[47] Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment
Aslanyan, Aram
Anwar-Hashim, Zoheb
Siripurapu, Rekha
Mihalova, Tatiana
BMJ CASE REPORTS, 2021, 14 (02)
[48] Injectable Disease-Modifying Therapy for Relapsing-Remitting Multiple Sclerosis: A Review of Adherence Data
Caon, Christina
Saunders, Carol
Smrtka, Jennifer
Baxter, Nancy
Shoemaker, Jennifer
JOURNAL OF NEUROSCIENCE NURSING, 2010, 42 (05) : S5 - S9
[49] Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)
Wiendl, Heinz
Gold, Ralf
Berger, Thomas
Derfuss, Tobias
Linker, Ralf
Maeurer, Mathias
Stangel, Martin
Aktas, Orhan
Baum, Karl
Berghoff, Martin
Bittner, Stefan
Chan, Andrew
Czaplinski, Adam
Deisenhammer, Florian
Di Pauli, Franziska
Du Pasquier, Renaud
Enzinger, Christian
Fertl, Elisabeth
Gass, Achim
Gehring, Klaus
Gobbi, Claudio
Goebels, Norbert
Guger, Michael
Haghikia, Aiden
Hartung, Hans-Peter
Heidenreich, Fedor
Hoffmann, Olaf
Hunter, Zoe R.
Kallmann, Boris
Kleinschnitz, Christoph
Klotz, Luisa
Leussink, Verena
Leutmezer, Fritz
Limmroth, Volker
Luenemann, Jan D.
Lutterotti, Andreas
Meuth, Sven G.
Meyding-Lamade, Uta
Platten, Michael
Rieckmann, Peter
Schmidt, Stephan
Tumani, Hayrettin
Weber, Martin S.
Weber, Frank
Zettl, Uwe K.
Ziemssen, Tjalf
Zipp, Frauke
NERVENARZT, 2021, 92 (08): : 773 - 801
[50] Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity
Alroughani, Raed
Inshasi, Jihad
Al-Asmi, Abdullah
Alqallaf, Abdulradha
Al Salti, Abdulla
Shatila, Ahmed
Boshra, Amir
Canibano, Beatriz
Deleu, Dirk
Al Sharoqi, Isa
Al Khabouri, Jaber
POSTGRADUATE MEDICINE, 2020, 132 (04) : 368 - 376

← 1 2 3 4 5 →